About: Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study
Creator	Lin, Zhenqiu Krumholz, Harlan Ko, Albert Lee, Charles Kuppusamy, Karthik Mahajan, Shiwani Rao, Lokinendi Redlich, Carrie Li, Shu-Xia Adams, Mark Anastasio, Kelly Cashman, Lisa Chattopadhyay, Manas Hodge, Domonique Huston, Sara Marlar, Jenny Srinivasan, Rajesh Stewart, Chris Witters, Dan
source	MedRxiv
abstract	Importance: A seroprevalence study can estimate the percentage of people with SARS-CoV-2 antibodies in the general population. Most existing reports have used a convenience sample, which may bias their estimates. Objective: To estimate the seroprevalence of antibodies against SARS-CoV-2 based on a random sample of adults living in Connecticut between March 1 and June 1, 2020. Design: Cross-sectional. Setting: We sought a representative sample of Connecticut residents who completed a survey between June 4 and June 23, 2020 and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and July 6, 2020. Participants: 505 respondents, aged [≥]18 years, residing in non-congregate settings who completed both the survey and the serology test. Main outcomes and measures: We estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies among the overall population and across pre-specified subgroups. We also assessed the prevalence of symptomatic illness, risk factors for virus exposure, and self-reported adherence to risk mitigation behaviors among this population. Results: Of the 505 respondents (mean age 50 [{+/-}17] years; 54% women; 76% non-Hispanic White individuals) included, 32% reported having at least 1 symptom suggestive of COVID-19 since March 1, 2020. Overall, 18 respondents had SARS-CoV-2-specific antibodies, resulting in the state-level weighted seroprevalence of 3.1 (90% CI 1.4-4.8). Individuals who were asymptomatic had significantly lower seroprevalence (0.6% [90% CI 0.0-1.5]) compared with the overall state estimate, while those who reported having had [≥]1 and [≥]2 symptoms had a seroprevalence of 8.0% (90% CI 3.1-12.9) and 13.0% (90% CI 3.5-22.5), respectively. All 9 of the respondents who reported previously having a positive coronavirus test were positive for SARS-CoV-2-specific IgG antibodies. Nearly two-third of respondents reported having avoided public places (74%) and small gatherings of family or friends (75%), and 97% reported wearing a mask outside their home, at least part of the time. Conclusions and relevance: These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-CoV-2. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents, to prevent resurgence of COVID-19 in this region.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1101/2020.08.04.20168203
has license	medrxiv
sha1sum (hex)	e8b2520f8223794e5e6afed548d688f0f74f189e
schema:url	https://doi.org/10.1101/2020.08.04.20168203
resource representing a document's title	Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study
resource representing a document's body	covid:e8b2520f8223794e5e6afed548d688f0f74f189e#body_text
is schema:about of	named entity 'population' named entity 'seroprevalence' named entity 'Seroprevalence' named entity 'estimates' named entity 'population characteristics' named entity 'copyright holder' named entity 'gold standard' named entity 'peer review' named entity 'infection' named entity 'Social isolation' named entity 'COVID-19' named entity 'serology' named entity 'medRxiv' named entity '95% CI' named entity 'blood test' named entity 'seroprevalence' named entity 'copyright holder' named entity 'preprint' named entity 'virus' named entity 'medRxiv' named entity 'health insurance' named entity 'diarrhea' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'preprint' named entity 'CC-BY-NC-ND 4.0' named entity 'peer review' named entity 'representative sample' named entity 'copyright holder' named entity 'SARS-CoV-2' named entity 'seroprevalence' named entity 'antibody test' named entity 'Connecticut' named entity 'Quest Diagnostics' named entity 'Quest Diagnostics' named entity 'preprint' named entity 'COVID' named entity 'copyright holder' named entity 'SARS-CoV-2' named entity 'copyright holder' named entity 'blood test' named entity 'vaccine' named entity 'assisted living' named entity 'SARS-CoV-2' named entity 'sample size' named entity 'copyright holder' named entity 'seroprevalence' named entity 'SARS-CoV-2' named entity 'seroprevalence' named entity 'copyright holder' named entity 'seroprevalence' named entity 'tested positive' named entity 'COVID-19' named entity 'Connecticut' named entity 'preprint' named entity 'Connecticut' named entity 'preprint' named entity 'seroprevalence' named entity 'preprint' named entity 'cough' named entity 'preprint' named entity 'June 10' named entity 'Connecticut' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'copyright holder' named entity 'seroprevalence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software